Analysis shows dual blockade of IL-33 and PD-1 pathways improves outcomes in breast cancer, suggesting potential for future clinical trials.
Dual blockade of PD-1/PD-L1 and IL-33/ST2 signalling pathways represents a novel and promising strategy to enhance the efficacy of immunotherapy in breast cancer. This approach has the potential to revert the immunosuppressive TME, leading to more durable and robust anti-tumour responses. Further research is warranted to validate this hypothesis and translate it into effective clinical trials.
No takes yet. Share an insight, caveat, or question.
Jovanović et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: